Insulin detemir in the treatment of type 1 and type 2 diabetes

Vascular Health and Risk Management

Volumn 2, Issue 3, 2006, Pages 277-283

  Philips, Jean Christophe ^a   Scheen, André ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Diabetes mellitus; Hypoglycemia; Insulin analogue; Insulin detemir; Insulin therapy

Indexed keywords

ALBUMIN; FATTY ACID; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LONG ACTING DRUG; SHORT ACTING DRUG;

BODY WEIGHT DISORDER; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG TOLERABILITY; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; REVIEW; RISK REDUCTION; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 33747799015     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: 10.2147/vhrm.2006.2.3.277     Document Type: Review

References (37)

1. Andreani D. 1999. Lights and shadows of insulin treatment seen by a senior diabetologist. Exp Clin Endocrinol Diabetes, 107: S1-5
2. Blumer I. 2006. Severe injection site reaction to insulin detemir. Diabetes Care, 29:946.
3. Chapman T, Perry C. 2004. Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs, 64:2577-95.
4. Chapman T, Perry C. 2005. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus. BioDrugs, 19:67-9.
5. Danne T, Lupke K, Walte K, et al. 2003. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care, 26:3087-92.
6. Darmon P, Castera V, Koeppel MC, et al. 2005. Type III allergy to insulin detemir. Diabetes Care, 28:2980.
7. [DCCT] Diabetes Control and Complications Trial Research Group. 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 329:977-86.
8. De Leeuw I, Vague P, Selam J, et al. 2005. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab, 7:73-82.
9. DeWitt D, Hirsch B. 2003. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA, 289:2254-64.
10. Fritsche A, Haring H. 2004. At last, a weight neutral insulin? Int J Obesity Relat Metab Disord, 28(Suppl 2):S41-6.
11. Haak T, Tiengo A, Waldhausl W, et al. 2003. Treatment with insulin detemir is associated with predictable fasting glucose levels and favourable weight development in subjects with type 2 diabetes [abstract]. Diabetologia, 46(Suppl 2):A120.
12. Havelund S, Plum A, Ribel U, et al. 2004. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res, 8:1498-504.
13. Heinemann L, Linkeschova R, Rave K, et al. 2000. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care, 23:644-9.
14. Heise T, Nosek L, Ronn BB,et al. 2004. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes, 53:1614-20.
15. Hermansen K, Madsbad T, Perilld H, et al. 2001. Comparison of soluble basal insulin analog detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care, 24:296-301.
16. Hermansen K, Derezinski T, Kim H, et al. 2004a. Treatment with insulin detemir in combination with oral agents is associated with less risk of hypoglycemia and less weight gain than NPH insulin at comparable levels of glycaemic improvement in people with type 2 diabetes [abstract]. Diabetologia, 47(Suppl 1):A273-4.
17. Hermansen K, Fontaine P, Kukolja K, et al. 2004b. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia, 47:622-9.
18. Hirsch IB. 2005. Insulin analogues. N Engl J Med, 352:174-83.
19. Home P, Bartley P, Russell-Jones D, et al. 2004. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care, 27:1081-7.
20. Hordern S, Wright J, Umpleby A, et al. 2005. Comparison of the effects on glucose metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia, 48:420-6
21. Jackson R. 1986. Historical background. In: Jackson RL, Guthrie RA (eds). The physiological management of diabetes in children. New York: Medical Examination Publishing, p 6-16.
22. Joslin EP. 1941. A diabetic manual for the mutual use of doctor and patient. 7th ed. Philadelphia: Lea & Febiger.
23. Kurtzhals P, Schaffer L, Sorensen A, et al. 2000. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes, 49:999-1005.
24. Kurtzhals P. 2004. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int J Obes Relat Metab Disord, 28(Suppl 2):S23-8.
25. McNally PG, Jowett NI, Kurinczuk JJ, et al. 1988. Lipohypertrophy and lipoatrophy complicating treatment with highly purified bovine and porcine insulins. Postgrad Med J, 64:850-3.
26. Mudaliar SR, Lindberg FA, Joyce M, et al. 1999. Insulin aspart (B28 aspinsulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care, 22:1501-6.
27. Oiknine R, Bernbaum M, Mooradian AD. 2005. A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. Drugs, 65:325-40.
28. Pieber T, Draeger E, Kristensen A, et al. 2005. Comparison of three multiple injection regimens for type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabetic Med, 22:850-7.
29. Plank J, Bodenlenz M, Sinner F, et al. 2005. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long acting insulin analog detemir. Diabetes Care, 28:1107-12.
30. Raslova K, Bogoev M, Raz I, et al. 2004. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract, 66:193-201.
31. Robertson K, Schonle E, Gucev Z, et al. 2004. Benefits of insulin detemir in children and adolescents with type 1 diabetes: lower and more predictable fasting glucose plasma and lower risk of nocturnal hypoglycemia (abstract). Diabetes, 53 (Suppl 2):A130-1.
32. Rosenfeld L. 2002. Insulin: discovery and controversy. Clin Chem, 48: 2270-88.
33. Russell-Jones D, Simpson R, Hylleberg B, et al. 2004. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther, 26:724-36.
34. Standl E, Lang H, Roberts A. 2004. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technol Ther, 6:579-88.
35. [UKPDS] UK Prospective Diabetes Study (UKPDS) Group. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352:837-53.
36. Vague P, Selam JL, Skeie S, et al. 2003. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care, 26:590-6.
37. Yki-Jarvinen, Dressler A, Ziemen M; HOE 901/300s Study Group. 2000. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care, 23:1130-6.